Eylward Susan sold $4K of IMNN

Eylward Susan (General Counsel and Corp Sec) sold 2,525 shares of Imunon, Inc. (IMNN) at $1.56 on 2026-08-31.

Original reporting
SEC EDGAR · Eylward Susan
Published Sep 1, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IMNN
Neutral
high confidence
Mentioned
$IMNN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMNNNeutralLow
01

Why it matters

The sale is modest and does not provide a new trading signal; it serves as a routine disclosure.

02

Market read

Limited relevance; primarily of interest to shareholders monitoring insider activity.

03

What to watch

Potential upcoming corporate actions not yet public.

Relevance 3/10Novelty 4/10Timing: Filed Sep 1, 2026 (same day as disclosure)

Background

SEC Form 4 filing reporting an insider's open‑market sale of IMNN shares.

Company-level read

Ticker impact

$IMNNNeutralHigh confidence
Context

General Counsel sold 2,525 shares for $3,950 on 2026-08-31, reducing holdings to 2,896 shares.

Expected impact

No material price impact expected.

Evidence & confidence

The transaction size is small relative to market cap and does not signal a change in outlook.

Market effects

None; insider sale does not affect sector dynamics.

None; limited to the issuing company.

None; no broader market relevance.

Counterpoint

If the insider is unusually bearish, could hint at undisclosed concerns.

Key entities

  • Imunon, Inc.

    Biotech firm listed on US exchanges under ticker IMNN.

  • Eylward Susan

    General Counsel and Corporate Secretary of Imunon, reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IMNNMedAI 8/10

Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

$IMNNLow

Imunon 3Q 2026: EPS ($0.64) — 10-Q Summary

Imunon (IMNN) reported a wider net loss of $3.81M in Q3 2026, though diluted EPS improved to ($0.64) from ($1.16) YoY. Operating expenses decreased 1%, with R&D costs down 6%. The OVATION 3 trial enrollment exceeded expectations, and the company advanced its NCI collaboration and MRD study. Imunon discontinued PLACCINE and IMNN-101 development in Q1 2026.

$IMNNMed

Imunon Reports Q3 2026 Net Loss of $3.8 Million and Advances IMNN-001

Imunon reported a Q3 2026 net loss of $3.8M, or $0.64 per share, compared to $3.4M, or $1.16 per share, a year earlier. Operating expenses were $3.4M. The company updated its Phase 3 ovarian cancer study and other programs, with enrollment expected to complete by Q1 2029. Imunon also transferred ThermoDox rights to VoxelDox, contingent on funding.

$IMNNHighAI 8/10

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

$IMNNHighAI 8/10

IMUNON presents translational data from ovarian cancer trial

IMUNON Inc. (IMNN) presented data from its Phase 2 OVATION 2 study of IMNN-001 in advanced ovarian cancer, showing improved survival and immune response. The trial compared IMNN-001 with chemotherapy against chemotherapy alone. The company is now conducting a Phase 3 trial, OVATION 3, to confirm these results. IMNN-001 is a DNA-based immunotherapy targeting IL-12 delivery to tumor tissue.

$IMNNMed

In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.